IDEAYA Biosciences Inc. (NASDAQ: IDYA) enrolled its first patient in a Phase 1 dose escalation trial for IDE034, an investigational ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE